Clinical Trial

An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer

Name: An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer — clinical trial record (NCT06613373)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 4

View on ClinicalTrials.gov →

Record status

This record was last updated September 25, 2024 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.

Summary

This is a single-arm, open-label, exploratory clinical study

Trial Details

NCT Number	NCT06613373
Lead Sponsor	Jiangsu Famous Medical Technology Co., Ltd.
Conditions	Breast Cancer
Enrollment	30 participants
Start Date	2024-10-15
Primary Completion	2025-10-30 (estimated)
Study Completion	2026-10-30 (estimated)
Updated on ClinicalTrials.gov	2024-09-25